Related references
Note: Only part of the references are listed.Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
Jeffrey E. Lancet et al.
BLOOD (2014)
Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia
E. J. Feldman et al.
LEUKEMIA RESEARCH (2012)
Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells
Hyun Pyo Kim et al.
EXPERIMENTAL HEMATOLOGY (2011)
First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Eric J. Feldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts
Wah-Seng Lim et al.
LEUKEMIA RESEARCH (2010)
Mouse models of human AML accurately predict chemotherapy response
Johannes Zuber et al.
GENES & DEVELOPMENT (2009)
In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy
Paul Tardi et al.
LEUKEMIA RESEARCH (2009)
Sequential influences of leukemia-specific and genetic factors on P-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trials
Claire H. Seedhouse et al.
CLINICAL CANCER RESEARCH (2007)
Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice
Lawrence D. Mayer et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Prognostic index for adult patients with acute myeloid leukemia in first relapse
DA Breems et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
EL Sievers et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
